Bavarian Nordic (OTCMKTS:BVNRY) Sets New 1-Year High – Here’s Why

Bavarian Nordic (OTCMKTS:BVNRY) shares hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $12.56 and last traded at $12.55, with a volume of 2,394 shares trading hands. The stock had previously closed at $12.43.

Bavarian Nordic Stock Up 1.0%

The firm has a fifty day moving average of $11.05 and a 200-day moving average of $10.07. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of 12.68 and a beta of 1.25.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its quarterly earnings data on Friday, August 21st. The company reported $0.46 EPS for the quarter. The firm had revenue of $316.47 million for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%.

Bavarian Nordic Company Profile

Bavarian Nordic A/S is a Denmark-based biotechnology and vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. The company supplies products to government agencies, public-health organizations, healthcare providers and private-sector customers in markets around the world.

Its best-known product is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for travelers and other infectious-disease risks, including products targeting rabies, tick-borne encephalitis, typhoid and cholera, as well as selected pediatric and adult immunization needs.

Founded in 1994 and headquartered in Copenhagen, Bavarian Nordic has expanded from a vaccine research company into an international commercial vaccine manufacturer.